# Sema4 to acquire GeneDx from OPKO Health

Sema4 announced a definitive agreement to acquire GeneDx, a subsidiary of OPKO Health, strengthening its genomic and clinical data platform. The deal is projected to deliver $350 million in pro forma 2022 revenue, with a $200 million private placement from investors including Pfizer.

- Type: Acquisition
- Announced: 2022-01-18
- Where: United States
- Status: announced
- Products: genomic testing, clinical data platform
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Sema4 Holdings Corp.](https://endata.com/companies/60412.md) (acquirer)
- [GeneDx](https://endata.com/companies/60413.md) (target)
- [OPKO Health](https://endata.com/companies/60414.md) (partner)

## Sources

- [nasdaq.com](https://www.nasdaq.com/press-release/sema4-to-acquire-genedx-strengthening-its-market-leading-ai-driven-genomic-and), 2022-01-18: "Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and OPKO Health, Inc. (Nasdaq: OPK) today announced they have signed a definitive agreement for Sema4 to acquire OPKO’s wholly owned subsidiary, GeneDx, Inc."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.